Human papillomavirus infection

Fujirebio Europe Expands Its Portfolio With Introduction of the Innovative PreCursor-M AnoGYN assay (RUO) for Methylation Testing in Anal Specimens

Retrieved on: 
Tuesday, March 5, 2024

Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.

Key Points: 
  • Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.
  • In analogy with cervical cancer screening, the screening and treatment of HSIL to prevent anal cancer in high-risk groups are under debate.
  • Host cell deoxyribonucleic acid methylation markers for the detection of high-grade anal intraepithelial neoplasia and anal cancer.
  • Analytical validation and diagnostic performance of the ASCL1/ZNF582 methylation test for detection of high-grade anal intraepithelial neoplasia and anal cancer.

Hybribio Calls for Raising International HPV Awareness

Retrieved on: 
Monday, March 4, 2024

On this special day, Hybribio (300639.SZ) calls for raising international HPV awareness and adopting effective strategies for early detection and prevention.

Key Points: 
  • On this special day, Hybribio (300639.SZ) calls for raising international HPV awareness and adopting effective strategies for early detection and prevention.
  • In this case, raising HPV awareness, getting timely vaccination and high-quality screening together contribute significantly to the prevention of HPV infection and related diseases.
  • Hybribio has developed a complete HPV molecular diagnostic solution covering 14 High-risk HPV GenoArray Diagnostic Kit, 14 High-risk HPV with 16/18 Genotyping Real-time PCR Kit, 14 High-risk HPV E6/E7 mRNA Real-time PCR Kit (PCR with Fluorescent Probe), 21 HPV GenoArray Diagnostic Kit, 37 HPV GenoArray Diagnostic Kit, 13 High-risk HPV Real-time PCR Kit, 23 HPV Genotyping Real-time PCR Kit, SOX1 and PAX1 Methylation Real-time PCR Kit.
  • Raising international HPV awareness is the very first step against cervical cancer.

Hybribio Calls for Raising International HPV Awareness

Retrieved on: 
Monday, March 4, 2024

On this special day, Hybribio (300639.SZ) calls for raising international HPV awareness and adopting effective strategies for early detection and prevention.

Key Points: 
  • On this special day, Hybribio (300639.SZ) calls for raising international HPV awareness and adopting effective strategies for early detection and prevention.
  • In this case, raising HPV awareness, getting timely vaccination and high-quality screening together contribute significantly to the prevention of HPV infection and related diseases.
  • Hybribio has developed a complete HPV molecular diagnostic solution covering 14 High-risk HPV GenoArray Diagnostic Kit, 14 High-risk HPV with 16/18 Genotyping Real-time PCR Kit, 14 High-risk HPV E6/E7 mRNA Real-time PCR Kit (PCR with Fluorescent Probe), 21 HPV GenoArray Diagnostic Kit, 37 HPV GenoArray Diagnostic Kit, 13 High-risk HPV Real-time PCR Kit, 23 HPV Genotyping Real-time PCR Kit, SOX1 and PAX1 Methylation Real-time PCR Kit.
  • Raising international HPV awareness is the very first step against cervical cancer.

HPV's Hidden Hand: New Study by Pusan National University Scientists Reveals Key Details in Head and Neck Cancer Microenvironment

Retrieved on: 
Wednesday, February 28, 2024

BUSAN, South Korea, Feb. 28, 2024 /PRNewswire/ -- Head and neck squamous cell carcinoma (HNSCC) is a type of cancer that affects the mucous membranes of the mouth, nose, and throat. HNSCC is typically associated with tobacco exposure, alcohol abuse, and viral infections. The links between human papillomavirus (HPV) infection status and the molecular characteristics of HNSCC are not clearly defined.

Key Points: 
  • BUSAN, South Korea, Feb. 28, 2024 /PRNewswire/ -- Head and neck squamous cell carcinoma (HNSCC) is a type of cancer that affects the mucous membranes of the mouth, nose, and throat.
  • The links between human papillomavirus (HPV) infection status and the molecular characteristics of HNSCC are not clearly defined.
  • Therefore, the HPV infection could be considered a criterion for developing treatment strategies, thereby enabling precision medicine tailored to the patient's condition!
  • Title of original paper: Deciphering Head and Neck Cancer Microenvironment: Single–Cell and Spatial Transcriptomics Reveals Human Papillomavirus–Associated Differences

BD Partners with Camtech Health to Increase Access to Cervical Cancer Screening in Singapore

Retrieved on: 
Wednesday, February 21, 2024

SINGAPORE, Feb. 21, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic partnership with Camtech Health, a digital health company focused on at-home health testing, to advance cervical cancer screening by offering the first-ever option for women in Singapore to self-collect a sample in the privacy of their own home.

Key Points: 
  • The program objective is to improve the rate of cervical cancer screening in Singapore, where less than half of eligible women are currently being tested.
  • "Cervical cancer is preventable, precancer is curable, and programs like this help to support the national goal of cervical cancer elimination.
  • In late 2020, the World Health Organization (WHO) launched its Global Strategy to Accelerate the Elimination of Cervical Cancer, recognizing the potential to virtually eliminate cervical cancer as a public health threat, recognizing the potential to eliminate cervical cancer in our lifetimeiii.
  • At-home collection can help address the urgent public health challenge of reaching women who do not attend routine cervical cancer screening.

BD, Techcyte Announce Strategic Collaboration to Offer AI-Based Digital Cervical Cytology System for Pap Testing

Retrieved on: 
Tuesday, January 30, 2024

FRANKLIN LAKES, N.J. and OREM, Utah, Jan. 30, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Techcyte, a world leader in artificial intelligence (AI)-based digital diagnostics, today announced a strategic collaboration agreement to offer an AI-based algorithm that guides cytologists and pathologists to efficiently and effectively identify evidence of cervical cancer and precancer using whole-slide imaging.

Key Points: 
  • With the digital cervical cytology system, the samples can be scanned, converted to a digital slide image, and then reviewed on a computer monitor in a lab or from a remote location.
  • In addition, the digital cervical cytology system uses an AI-based algorithm to prioritize and present clinically relevant cells for visual evaluation.
  • "Eye strain, fatigue, distractions, and intense workloads can make manually reading Pap smears difficult," said Ben Cahoon, CEO of Techcyte.
  • "Our digital workflow supported by an AI-based algorithm can assist lab professionals in delivering consistent results for their patients.

Enhancing Leadership in Gynecology, Asieris Pharmaceuticals Appoints Sophia Cao to Lead the Newly-Established Women's Health Business Unit, Accelerating Strategic Expansion

Retrieved on: 
Tuesday, January 9, 2024

This strategic move is designed to enhance the company's focus on genitourinary diseases and strengthen its position in women's health.

Key Points: 
  • This strategic move is designed to enhance the company's focus on genitourinary diseases and strengthen its position in women's health.
  • Asieris Pharmaceuticals will leverage both in-house discoveries and external partnerships to enrich its gynecological portfolio, thereby reinforcing its leadership in women's health.
  • In November 2020, the World Health Organization (WHO) released a Global Strategy to Accelerate the Elimination of Cervical Cancer.
  • To further deliver its strategic vision and commitment in the realm of women's health, Asieris Pharmaceuticals has announced the establishment of the Women's Health Business Unit.

Qvin™ Introduces Q-Pad™: Transforming Women's Health with FDA-Cleared Lab Testing using Menstrual Blood

Retrieved on: 
Monday, January 8, 2024

SAN FRANCISCO, Jan. 8, 2024 /PRNewswire/ -- Qvin™, the biotechnology research company that developed the first and only healthcare service that collects menstrual blood samples as an alternative to traditionally collected venous blood draws, today announced FDA clearance of its Q-Pad™ and A1c Test. The clearance makes it possible for the millions of women in America who live with diabetes to receive monitoring of A1c, using laboratory tests performed on the Q-Pad. More broadly, this marks an opportunity for testing important biomarkers for the more than 80 million people who menstruate in the U.S.

Key Points: 
  • The traditional methods of blood testing require invasive procedures administered by medical professionals, and those can be time-consuming and expensive.
  • And yet, menstrual samples had never previously been explored as a diagnostic source for health information.
  • "Utilizing menstrual samples, the Q-Pad can address critical women's health issues that have historically been neglected," stated Søren Therkelsen, Co-founder of Qvin.
  • "For instance, women seeking to understand their fertility status can soon monitor various reproductive hormones via menstrual blood using the Q-Pad.

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

Retrieved on: 
Friday, January 5, 2024

OXFORD, United Kingdom, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today provided a preliminary financial update and announced its 2024 corporate objectives.

Key Points: 
  • OXFORD, United Kingdom, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today provided a preliminary financial update and announced its 2024 corporate objectives.
  • Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.
  • “2024 promises to be another exciting year for Barinthus Bio, with multiple data readouts expected across our hepatitis B virus (HBV) infection, human papillomavirus (HPV) infection and prostate cancer programs, as well as the planned initiation of the first in human study of our SNAP platform-based candidate VTP-1000 in Celiac Disease,” said Gemma Brown, Chief Financial Officer of Barinthus Bio.
  • * Barinthus Bio has worldwide rights for all product candidates.

Confusion about insurance coverage for cervical cancer screenings contributes to missed screening

Retrieved on: 
Wednesday, January 3, 2024

The 2023 survey shows 41% of American women are not up to date on cervical cancer screenings.2 This indicates an urgent need to discuss the cost of cervical cancer screening, as many people may be unaware cervical cancer screenings are covered through Medicaid and most private insurance plans.

Key Points: 
  • The 2023 survey shows 41% of American women are not up to date on cervical cancer screenings.2 This indicates an urgent need to discuss the cost of cervical cancer screening, as many people may be unaware cervical cancer screenings are covered through Medicaid and most private insurance plans.
  • That means, under current law, if you have health insurance and you have a cervix, your cervical cancer screenings are covered.
  • The elimination of cervical cancer will be severely hindered without proper education across all populations about screening, insurance coverage and HPV vaccination.
  • 2The cancer screenings studied in this survey were for breast cancer, cervical cancer, colorectal cancer, oral cancer, lung cancer, prostate cancer, skin cancer and testicular cancer.